On September 26, 2019 AVEO Oncology (NASDAQ:AVEO) reported that Michael Bailey, president and chief executive officer, will present at the 2019 Cantor Fitzgerald Global Healthcare Conference in New York on Friday, October 4, 2019 at 10:05 a.m. Eastern Time (Press release, AVEO, SEP 26, 2019, View Source [SID1234539826]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation can be accessed by visiting the investors section of the Company’s website at www.aveooncology.com. A replay of the webcast will be archived for 30 days following the presentation date.

On September 26, 2019 Baxter International Inc. (NYSE: BAX), a global leader in clinical nutrition reported that it will present at the ESMO (Free ESMO Whitepaper) congress to be held in Barcelona from 27 September to 1 October, organizing the symposium "Early and effective nutritional therapy in GI cancer patients: an opportunity to improve outcome (Press release, Baxter International, SEP 26, 2019, View Source [SID1234539825])."

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Approximately 50% of oncology patients in Europe are affected by malnutrition. While the rate of malnutrition is even higher for patients with gastrointestinal (GI) cancers real-world evidence suggests that only 23% of GI cancer patients have malnutrition diagnosed, due to the lack of appropriate nutritional screening.1 Approximately one quarter of all cancer patients die due to consequences of malnutrition, but cancer-related malnutrition goes undiagnosed in many patients.2

Seven out of ten patients experience feeding problems during cancer treatment, chemotherapy and radiotherapy, leaving them at serious risk of malnutrition and its associated problems.3

Early initiation of clinical nutrition therapy after cancer diagnosis allows to achieve the best possible patient outcomes, improvement of cancer care and optimisation of healthcare resources use.4,5 Parenteral nutrition is a life-sustaining therapy when oral and enteral nutrition are not possible.

1 Tlemsani C et al. (2018) Malnutrition in cancer patients: is a late diagnosis a missed opportunity to improve care? Ann Oncol 29: viii603-40.
2 Hu W-H et al. (2015). Nutr J 14: 91. Lee H et al. (2013) Clin Nutr Res 2: 12-8.
3 ECPC Nutrition Booklet, 2018.
4 Tlemsani C et al. (2018) Malnutrition in cancer patients: is a late diagnosis a missed opportunity to improve care? Ann Oncol 29: viii603-4
5 Goldwasser, F et al. Challenges and Opportunities in Clinical Nutrition in Oncology: Available Evidence, Real-World Practices and the Way Forward, 2018.

On September 26, 2019 DURECT Corporation (Nasdaq: DRRX) reported that James E. Brown, Chief Executive Officer will be presenting at the Cantor Fitzgerald Global Health Care Conference, at the InterContinental New York Barclay Hotel on Friday, October 4, 2019 at 10:40 a.m. EDT (Press release, DURECT, SEP 26, 2019, https://investors.durect.com/news-releases/news-release-details/durect-present-2019-cantor-fitzgerald-global-health-care [SID1234539823]). Institutional investors and analysts that are attending the conference may request a one-on-one meeting through the conference coordinators.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast of the presentation will be available by accessing View Source

The live audio webcast of the presentation will also be available by accessing DURECT’s homepage at www.durect.com and clicking on the "Investors" tab. If you are unable to participate during the live webcast, the call will be archived on DURECT’s website in the "Event Calendar" of the "Investors" section.

On September 26, 2019 Verastem, Inc. (Nasdaq: VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients, reported that the Company will present at the Cantor 2019 Global Healthcare Conference on Thursday, October 3, 2019 at 8:20 a.m. EDT in New York, NY (Press release, Verastem, SEP 26, 2019, View Source [SID1234539822]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be available on the investors section of the Company’s website at www.verastem.com. An archived presentation will be available for 90 days.

On September 26, 2019 Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune disease, asthma and allergic diseases, reported that company management will present at the 2019 Cantor Global Healthcare Conference on Thursday, October 3, 2019 at 8:55 a.m. ET in New York (Press release, Xencor, SEP 26, 2019, View Source [SID1234539821]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast will be available under "Events & Presentations" in the Investors section of the Company’s website located at www.xencor.com. A replay of the event will be posted on the Xencor website approximately one hour after the live event and will be available for 30 days following the presentation.